Abstract

Glutathione transferase Omega 1 (GSTO1-1) is an atypical GST reported to play a pro-inflammatory role in response to LPS. Here we show that genetic knockout of Gsto1 alters the response of mice to three distinct inflammatory disease models. GSTO1-1 deficiency ameliorates the inflammatory response stimulated by LPS and attenuates the inflammatory impact of a high fat diet on glucose tolerance and insulin resistance. In contrast, GSTO1-1 deficient mice show a more severe inflammatory response and increased escape of bacteria from the colon into the lymphatic system in a dextran sodium sulfate mediated model of inflammatory bowel disease. These responses are similar to those of TLR4 and MyD88 deficient mice in these models and confirm that GSTO1-1 is critical for a TLR4-like pro-inflammatory response in vivo. In wild-type mice, we show that a small molecule inhibitor that covalently binds in the active site of GSTO1-1 can be used to ameliorate the inflammatory response to LPS. Our findings demonstrate the potential therapeutic utility of GSTO1-1 inhibitors in the modulation of inflammation and suggest their possible application in the treatment of a range of inflammatory conditions.

Details

Title
GSTO1-1 plays a pro-inflammatory role in models of inflammation, colitis and obesity
Author
Menon, Deepthi 1 ; Innes, Ashlee 2 ; Oakley, Aaron J 3 ; Dahlstrom, Jane E 4 ; Jensen, Lora M 2 ; Brüstle, Anne 2 ; Tummala, Padmaja 2 ; Rooke, Melissa 2 ; Casarotto, Marco G 2 ; Baell, Jonathan B 5   VIAFID ORCID Logo  ; Nguyen, Nghi 6   VIAFID ORCID Logo  ; Xie, Yiyue 6 ; Cuellar, Matthew 7   VIAFID ORCID Logo  ; Strasser, Jessica 7   VIAFID ORCID Logo  ; Dahlin, Jayme L 8 ; Walters, Michael A 7   VIAFID ORCID Logo  ; Burgio, Gaetan 2   VIAFID ORCID Logo  ; Luke A J O’Neill 9 ; Board, Philip G 2   VIAFID ORCID Logo 

 John Curtin School of Medical Research, Australian National University, Canberra, Australia; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland 
 John Curtin School of Medical Research, Australian National University, Canberra, Australia 
 School of Chemistry, University of Wollongong, Wollongong, NSW, Australia 
 ACT Pathology and ANU Medical School, The Canberra Hospital, Garran, Australia 
 Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, People’s Republic of China 
 Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia 
 Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN, USA 
 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA 
 School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland 
Pages
1-15
Publication year
2017
Publication date
Dec 2017
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1983429805
Copyright
© 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.